BUPARVALEK

Buparvakvon is highly active against theileria both in the stage of schizonts and piroplasma stage.
Mechanism of buparvakvon action is currently not fully identified. Presumably, it breaks Theileria’s
mechanism of electron transport in mitochondria.

Application of buparvakvon on the level of cellular structures leads to progressive vacuolization in cytoplasm of parasites, which eventually leads to disruption of the outer membrane structure and nuclear membrane of parasites. At the same time buparvakvon does not affect intracellular structures (including mitochondria), where Theileria is parasitized.

During intramuscular administration the drug is retained in tissues for long time. The period for
buparvakvon semi-withdrawal is about 7 days.

The drug is used as a single dose 1 ml per 20 kg of body weight, which is 2.5 mg of buparvakvon per 1 kg. Method of administration is intramuscularly in the neck area. In severe cases the drug is administered again in the same dose 48-72 hours after the first injection.

Specific instructions. Do not inject more than 10 ml of the drug to a single point injection. If necessary, administered dosage shall be divided in two and injected on both sides of the neck.

Buparvalek is administered in cattle with therapeutic and preventive purposes against theileriosis caused by so called Theiriaparva, T. annulata, T. mutans, and T. orientalis.

Sometimes local but not painful edema and swelling on the injection site may occur, which disappear in due course.

CONTRAINDICATIONS: Do not administer the drug subcutaneously or intravenously.

Slaughter of animals for meat shall be allowed 42 days after the last drug administration. Consumption of milk for food purposes is restricted for 2 days after the last drug injection.